Macomics™ lead programme, MACO-355, in IND enabling studies is a ligand-blocking independent pan-LILR monoclonal antibody for the treatment of cancerData presented at AACR 2024 shows MACO-355 is...
EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent...
EDINBURGH and CAMBRIDGE, United Kingdom, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, continues its growth trajectory with expansion in Edinburgh into...
Macomics Presents its ENIGMACâ„¢ Discovery Platform for Gene to Function Target Validation of Novel Macrophage Therapies at AACR
Macomics and Ono Pharmaceutical Partner to Discover and Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer
Macomics Ltd., a drug discovery company, entered into a worldwide drug discovery collaboration agreement with Ono Pharmaceutical Co., to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer.